Bibliography
- 1 Yamanaka S: Identification of factors that generate ES-like pluripotent cells from fibroblast culture. Presented at: 4th International Society for Stem Cell Research. Ontario, Canada, 29 June–1 July (2006).
- 2 Gaines P, Liu R, Park I-H: Research Highlights. Regen. Med.5(4),501–503 (2010).
- 3 Grskovic M, Seidenman K, Dimos JT: Cell programming: jumping back to pluripotency or rewiring fate. Regen. Med.5(4),493–495 (2010).
- 4 Walker J: Disease in a dish: a new approach to drug discovery. Regen. Med.5(4),505–507 (2010).
- 5 Ye Z, Cheng L: Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types. Regen. Med.5(4),521–530 (2010).
- 6 Huang K, Fan G: DNA methylation in cell differentiation and reprogramming: an emerging systematic view. Regen. Med.5(4),531–544 (2010).
- 7 Lakshmipathy U, Davila J, Hart RP: miRNA in pluripotent stem cells. Regen. Med.5(4),545–555 (2010).
- 8 West MD, Homayoun V: Back to immortality: the restoration of embryonic telomere length during induced pluripotency. Regen. Med.5(4),485–488 (2010).
- 9 Flynn P, Yingling J, Shoemaker D: Converging technologies to enable induced pluripotent stem cells in drug discovery. Regen. Med.5(4),489–491 (2010).
- 10 Rowntree RK, McNeish JD: Induced pluripotent stem cells: opportunities as research and development tools in 21st century drug discovery. Regen. Med.5(4),557–568 (2010).
- 11 Georgieva BP, Love JM: Human induced pluripotent stem cells: review of the US patent landscape. Regen. Med.5(4),581–591 (2010).
- 12 Carpenter MK, Couture LA: Regulatory considerations for the development of autologous iPS cell therapies. Regen. Med.5(4),569–579 (2010).
- 13 Smith D: Commercialization challenges associated with induced pluripotent stem cell-based products. Regen. Med.5(4),593–603 (2010).
- 14 Csete M: Translational prospects for human induced pluripotent stem cells. Regen. Med.5(4),509–519 (2010).